Since the first anti-HER2 monoclonal antibody, trastuzumab, was introduced into the treatment of HER2-positive breast cancer, new anti-HER2 agents have been developed and incorporated into the armamentarium over two decades. Here, ERBB2 is linked to breast carcinoma.